CA2289119A1 - Procede de traitement de l'inflammation ou de maladies inflammatoires a l'aide d'inhibiteurs de poly-adp ribose polymerase - Google Patents

Procede de traitement de l'inflammation ou de maladies inflammatoires a l'aide d'inhibiteurs de poly-adp ribose polymerase Download PDF

Info

Publication number
CA2289119A1
CA2289119A1 CA002289119A CA2289119A CA2289119A1 CA 2289119 A1 CA2289119 A1 CA 2289119A1 CA 002289119 A CA002289119 A CA 002289119A CA 2289119 A CA2289119 A CA 2289119A CA 2289119 A1 CA2289119 A1 CA 2289119A1
Authority
CA
Canada
Prior art keywords
amino
compound
group
alkoxy
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002289119A
Other languages
English (en)
Other versions
CA2289119C (fr
Inventor
Ernest Kun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octamer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/855,616 external-priority patent/US5908861A/en
Application filed by Individual filed Critical Individual
Publication of CA2289119A1 publication Critical patent/CA2289119A1/fr
Application granted granted Critical
Publication of CA2289119C publication Critical patent/CA2289119C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Procédé de traitement de l'inflammation ou des maladies inflammatoires chez un animal ou un mammifère, qui consiste à administrer à cet animal ou mammifère une quantité efficace d'un composé inhibiteur de poly-ADP ribose polymérase (pADPRT).
CA2289119A 1997-05-13 1998-05-13 Procede de traitement de l'inflammation ou de maladies inflammatoires a l'aide d'inhibiteurs de poly-adp ribose polymerase Expired - Fee Related CA2289119C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/855,616 1997-05-13
US08/855,616 US5908861A (en) 1997-05-13 1997-05-13 Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US09/056,396 US6303629B1 (en) 1997-05-13 1998-04-06 Methods for treating inflammation, inflammatory diseases, arthritis and stroke using pADPRT inhibitors
US09/056,396 1998-04-06
PCT/US1998/010033 WO1998051308A1 (fr) 1997-05-13 1998-05-13 Procede de traitement de l'inflammation ou de maladies inflammatoires a l'aide d'inhibiteurs de poly-adp ribose polymerase

Publications (2)

Publication Number Publication Date
CA2289119A1 true CA2289119A1 (fr) 1998-11-19
CA2289119C CA2289119C (fr) 2011-03-15

Family

ID=26735288

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2289119A Expired - Fee Related CA2289119C (fr) 1997-05-13 1998-05-13 Procede de traitement de l'inflammation ou de maladies inflammatoires a l'aide d'inhibiteurs de poly-adp ribose polymerase

Country Status (9)

Country Link
EP (1) EP1009404A4 (fr)
JP (1) JP4362638B2 (fr)
CN (1) CN1198614C (fr)
AU (2) AU745790B2 (fr)
BR (1) BR9809115A (fr)
CA (1) CA2289119C (fr)
IL (1) IL132758A0 (fr)
NZ (1) NZ501650A (fr)
WO (2) WO1998051308A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO121778B1 (ro) 1999-01-11 2008-04-30 Agouron Pharmaceuticals, Inc. Inhibitori triciclici de poli(adp-riboza) polimerază
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
ATE355278T1 (de) 2001-05-08 2006-03-15 Kudos Pharm Ltd Isochinolinon derivate als parp inhibitoren
AU2003229953A1 (en) 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
KR20080031266A (ko) * 2005-06-10 2008-04-08 바이파 사이언스 인코포레이티드 Ｐａｒｐ 조절제 및 암의 치료
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CA2662337A1 (fr) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition de la synthese d'acides gras au moyen d'inhibiteurs parp et methodes de traitement associees
CA2662335A1 (fr) * 2006-09-05 2008-03-13 Valeria Ossovskaya Procedes de conception d'inhibiteurs de parp et leurs utilisations
CN101641013B (zh) 2007-01-22 2014-07-30 Gtx公司 核受体结合剂
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
KR20100059950A (ko) 2007-09-14 2010-06-04 아스트라제네카 아베 프탈라지논 유도체
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
DK2346837T3 (en) 2008-06-26 2015-04-20 Resverlogix Corp Methods for preparing quinazolinone derivatives
UA106878C2 (uk) 2008-10-07 2014-10-27 Астразенека Юк Лімітед Фармацевтична композиція, що містить 4-[3-(4-циклопропанкарбонілпіперазин-1-карбоніл)-4-фторбензил]-2н-фталазин-1-он або його сіль, або сольват, у твердій дисперсії з матричним полімером коповідоном
WO2010061908A1 (fr) 2008-11-28 2010-06-03 中外製薬株式会社 Dérivé de 1-(2h)-isoquinolone
EP2660238B1 (fr) 2009-01-08 2015-05-06 Resverlogix Corporation Composés pour la prévention et le traitement d'une maladie cardiovasculaire
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
PT2421533T (pt) 2009-04-22 2019-01-21 Resverlogix Corp Novos agentes anti-inflamatórios
EP2773354B1 (fr) 2011-11-01 2019-06-12 Resverlogix Corp. Compositions pharmaceutiques a la liberation immediate pour l'administration orale des quinazolinones substituées
WO2014080291A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Dérivés biaryle servant d'inhibiteurs de bromodomaines
WO2014080290A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Amines cycliques servant d'inhibiteurs de bromodomaines
MX2015007921A (es) 2012-12-21 2016-03-03 Zenith Epigenetics Corp Compuestos heterociclicos novedosos como inhibidores de bromodominio.
CN107530356A (zh) 2015-03-13 2018-01-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
EP3687501A4 (fr) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. Formulations d'iniparib et leurs utilisations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6518890A (en) * 1989-09-26 1991-04-28 Regents Of The University Of California, The 6-amino-1,2-benzopyrones useful for treatment of viral diseases
US5484951A (en) 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5482975A (en) 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5516941A (en) 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5473074A (en) 1991-10-22 1995-12-05 Octamer, Incorporated Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54
DE4436127A1 (de) 1994-09-27 1996-03-28 Deutsches Rheumaforschungszent Verwendung von aromatischen Amiden und Säuren zur Behandlung von rheumatischen Erkrankungen
AU5259296A (en) * 1995-04-07 1996-10-23 Warner-Lambert Company Flavones and coumarins as agents for the treatment of athero sclerosis
US10766598B2 (en) 2017-06-14 2020-09-08 The Boeing Company Wing-to-fuselage joints and aircraft including the same

Also Published As

Publication number Publication date
NZ501650A (en) 2001-11-30
CA2289119C (fr) 2011-03-15
JP4362638B2 (ja) 2009-11-11
EP1009404A4 (fr) 2009-07-01
BR9809115A (pt) 2002-01-02
AU7484798A (en) 1998-12-08
IL132758A0 (en) 2001-03-19
EP1009404A1 (fr) 2000-06-21
WO1998051308A1 (fr) 1998-11-19
CN1198614C (zh) 2005-04-27
AU745790B2 (en) 2002-03-28
WO1998051307A1 (fr) 1998-11-19
AU7492698A (en) 1998-12-08
JP2002502367A (ja) 2002-01-22
CN1261278A (zh) 2000-07-26

Similar Documents

Publication Publication Date Title
CA2289119A1 (fr) Procede de traitement de l'inflammation ou de maladies inflammatoires a l'aide d'inhibiteurs de poly-adp ribose polymerase
MY127894A (en) Renin inhibitors
BG106867A (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases
MXPA04004301A (es) Bencimidazoles sustituidos utiles como inhibidores de la proteina cinasa.
ATE168101T1 (de) Arylpyridazinone
EP1120417A3 (fr) Dérivés de xanthine pour le traitement des troubles cérébrovasculaires
CA2316349A1 (fr) Compositions et procede pour la protection de la peau contre une immuno-suppression ou des lesions provoquees par les rayons uv
DK0597088T3 (da) Nye imidazolderivater, deres fremstilling og terapeutiske anvendelser
CA2195262A1 (fr) Composes de phosphonate nucleotidique
CO5261493A1 (es) Procedimiento y compuestos para la inhibicion de la mrp1
KR930701415A (ko) 약학적으로 활성인 벤조퀴나졸린 화합물
DK0654041T3 (da) Peptidyl-4-amino-2,2-difluor-3-oxo-1,6-hexandisyre-derivater som anto-inflammatoriske midler
CA2188690A1 (fr) Inhibiteurs selectifs de la thrombine
CA2192555A1 (fr) Compose de 2-acylaminopropanol et composition medicinale
CA2507657A1 (fr) Composes de 2-aminocarbonyl-quinoline utilises en tant qu'antagonistes du recepteur de l'adenosine diphosphate des plaquettes
CA2461218A1 (fr) Agonistes muscariniques
AP2000001761A0 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.
CA2575512A1 (fr) Derives de quinazoline utiles pour le traitement de la maladie arterielle peripherique et en tant qu'inhibiteurs de la phosphodiesterase
CA2126518A1 (fr) Utilisation de phenylalkylamines
CA2235298A1 (fr) Derives d'isoxazole
PT83345B (pt) Processo para a preparacao de gama-carbolinas antipsicoticas
PT1303514E (pt) Processo para preparacao de azacicloalcanoilaminotiazoles
HUP0004317A2 (hu) 5-HT1F agonisták
AP2000001760A0 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.
LV10951A (lv) 4-Hinolinilatvasinajumi

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170515